Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly FCF Margin of 2302.46% for Q2 2025, up 5495554.0% year-over-year from N/an in Q2 2024, and up 94.62% quarter-over-quarter from 42769.0% in Q4 2024.
Powered by 
Analysis
Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported FCF Margin for 3 consecutive years, with 2302.46% the latest figure, recorded in Q2 2025.
- In Q2 2025, FCF Margin rose 5495554.0% year-over-year to 2302.46%; the TTM figure through Dec 2025 stood at 9273.21% (up 146866.0% YoY), while the FY2025 annual figure was 9986.54%, up 8851646.0% from the prior year.
- FCF Margin improved to 2302.46% in Q2 2025 per INBX's latest filing, from 42769.0% in the prior quarter.
- Across five years, FCF Margin topped out at 2302.46% in Q2 2025 and bottomed at 57258.0% in Q2 2024.
- Historically, FCF Margin has averaged 30513.76% across 3 years, with a median of 42769.0% in 2024.
- Annual changes were most pronounced in 2024 — FCF Margin plunged 3908093 bps — and 2025, when it surged 5495554 bps.
- Inhibrx Biosciences' FCF Margin stood at 3688.07% in 2023, then tumbled by 1060 bps to 42769.0% in 2024, then jumped by 95 bps to 2302.46% in 2025.
- Business Quant data shows INBX's FCF Margin at 2302.46% in Q2 2025, 42769.0% in Q4 2024, and 57258.0% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2,304.54% |
| Dec 31, 2024 | -43,839.00% |
| Jun 30, 2024 | -59,517.00% |
| Dec 31, 2023 | -3,688.07% |
| Sep 30, 2023 | -46,062.18% |